Literature DB >> 2507452

Effect of IFN-gamma treatment and in vivo passage of murine tumor cell lines on their sensitivity to lymphokine-activated killer (LAK) cell lysis in vitro; association with H-2 expression on the target cells.

L Tsai1, C Ohlén, H G Ljunggren, K Kärre, M Hansson, R Kiessling.   

Abstract

Interferon-gamma (IFN-gamma) treatment or in vivo passage of the murine YAC-1 lymphoma resulted in reduced sensitivity to in vitro lysis by syngeneic murine spleen cells cultured in rIL-2 (LAK-cells). IFN-gamma treatment also rendered the murine B16 melanoma less sensitive to lysis by syngeneic LAK cells, whereas in vivo passage did not alter LAK sensitivity. The reduction in sensitivity to lysis correlated with enhanced expression of cell surface H-2 on the target cells. The possible role of H-2 was studied with a beta 2-microglobulin-deficient, and thus H-2-deficient, variant of the YAC-1 lymphoma. This variant line remained H-2 negative even after IFN-gamma treatment or in vivo passage, and was highly sensitive to LAK-cell-mediated lysis, even after IFN-gamma treatment or in vivo passage. The present results are discussed in relation to IFN-gamma and in vivo induced modulation of MHC class-1 molecules on target cells and the possible consequences for interaction with activated as well as "natural" effector cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507452     DOI: 10.1002/ijc.2910440419

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Authors:  Y Tomita; H Watanabe; H Kobayashi; T Nishiyama; S Tsuji; M Fujiwara; S Sato
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.

Authors:  M Maio; M Altomonte; R Tatake; R A Zeff; S Ferrone
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Role of major histocompatibility complex class I antigens in modulating the performance of murine tumour cells in cold target competition assays.

Authors:  V Haridas; R K Saxena
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

5.  Effect of interferon gamma on the sensitivity of bovine-papilloma-virus(BPV1)-transformed cell lines to cell-mediated cytotoxicity.

Authors:  A Laatikainen; L Schultz-Suhonen; R Mäntyjärvi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.

Authors:  T S Kim; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

7.  Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.

Authors:  Ezogelin Oflazoglu; Mark Elliott; Hiroshi Takita; Soldano Ferrone; Robert A Henderson; Elizabeth A Repasky
Journal:  J Transl Med       Date:  2007-06-25       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.